

## REMARKS

Claims 1-21 have been canceled and are no longer at issue.

The Examiner's indication of the allowability of claims 22-25 has been noted and these claims have been amended, where necessary, to avoid each formal ground of rejection.

The specification has been amended at page 9, line 15 and at page 19, line 25 to respectively add the term SEQ ID NO. 1 and to indicate that Botolina is a registered trademark.


Claim 22 has been revised to delete the expression "at least one peptide and to add the term "SED ID No.1" to the formula of the pentapeptide. The term "the" as used in conjunction with the term "dipeptide" has been deleted and the article "a" has been inserted. In claim 23, the term "comprises sodium-potassium has been substituted for the term "mixture of sodium-potassium" which has been deleted.

Claims 24 and 25 were objected to as depending on a rejected base claim. Since claim 22 has been amended to avoid the rejection under 35 U.S.C. §112, second paragraph, it is believed that claims 24 and 25 are now allowable as they now depend from allowable claim 22.

The cancellation of claims 1-21 has rendered the rejections of those claims moot. For these reasons, it is believed that this Amendment places the application in condition for allowance.

An early and favorable action is earnestly solicited.

Respectfully submitted,



James V. Costigan  
Registration No. 25,669

Hedman & Costigan, P.C.  
1185 Avenue of the Americas  
New York, NY 10036  
(212) 302-8989